References
Klinov V.V. New mechanisms of natural immunity: NLRP3 inflammasome. Department of Immunology and Allergology. Siberian State Medical University. URL: http://ssmu.immunology.sibhost.ru/IM/inflammasome_ru.html (Accessed: 07.11.2023) (In Russ.)
Nasonov E.L., Popkova T.V. Anti-inflammatory therapy for atherosclerosis: contribution of and lessons of rheumatology. Rheumatology Science and Practice, 2017, No. 55 (5), pp. 465-473. (In Russ.)
Broz P., Dixit V.M. Inflammasomes: mechanism of assembly, regulation and signalling. Nature Reviews Immunology, 2016, No. 16 (7), pp. 407-420.
Getz G.S., Reardon C.A. Use of mouse models in atherosclerosis research. Methods in Mouse Atherosclerosis, 2015, No. 1339, pp. 1-16.
Hansson G.K., Libby P., et al. Inflammation and plaque vulnerability. Journal of Internal Medicine, 2015, No. 278 (5), pp. 483-493.
Karasawa T., Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2017, No. 24 (5), pp. 443-451.
Ketelhuth D.F., Lutgens E., et al. Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovascular Research, 2019, No. 115 (9), pp. 1385-1392.
Ridker P.M., Howard C.P., et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation, 2012, No. 126 (23), pp. 2739-2748.
Ridker P.M., Everett B.M., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 2017, No. 377 (12), pp. 1119-1131.
Shao B.Z., Xu H.Y., et al. NLRP3 inflammasome in atherosclerosis: putting out the fire of inflammation. Inflammation, 2023, No. 46 (1), pp. 35-46.
Silvis M.J., Demkes E.J., et al. Immunomodulation of the NLRP3 inflammasome in atherosclerosis, coronary artery disease, and acute myocardial infarction. Journal of Cardiovascular Translational Research, 2021, No. 14, pp. 23-34.
Zhang Y., Li X., et al. Coronary endothelial dysfunction induced by nucleotide oligomerization domain-like receptor protein with pyrin domain containing 3 inflammasome activation during hypercholesterolemia: beyond inflammation. Antioxidants & Redox Signaling, 2015, No. 22 (13), pp. 1084-1096.